Literature DB >> 4858339

Diabetes in remission. Insulin secretory dynamics.

B N Park, R E Gleason, J S Soeldner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4858339     DOI： 10.2337/diab.23.7.616

Source DB:  PubMed          Journal:  Diabetes        ISSN： 0012-1797            Impact factor:   9.461


× No keyword cloud information.
  7 in total

1.  The transient effect of strict glycaemic control on B cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients.

Authors:  S Madsbad; T Krarup; O K Faber; C Binder; L Regeur
Journal:  Diabetologia       Date:  1982-01       Impact factor: 10.122

2.  Evidence for a direct action of exogenous insulin on the pancreatic islets of diabetic mice: islet response to insulin pre-incubation.

Authors:  C Gordon; A P Yates; D Davies
Journal:  Diabetologia       Date:  1985-05       Impact factor: 10.122

3.  Relation between the degree of initial metabolic decompensation and the duration of the remission phase in type I diabetes mellitus.

Authors:  U Vetter; E Heinze; E Kohne; W M Teller; E Kleihauer
Journal:  Eur J Pediatr       Date:  1982-02       Impact factor: 3.183

4.  Remission of diabetes mellitus in a geriatric patient.

Authors:  S A Peter
Journal:  J Natl Med Assoc       Date:  1984-06       Impact factor: 1.798

5.  The effect of glucose, tolbutamide, and arginine on C-peptide release during remission in type I diabetes mellitus.

Authors:  U Vetter; E Heinze; A Thon; W Beischer; W Teller
Journal:  Eur J Pediatr       Date:  1983-09       Impact factor: 3.183

6.  Sustained initial remission induced by intensive insulin treatment in type I diabetes. Possible role of the genetic background.

Authors:  P Vague; B Vialettes; V Lassmann; J P Moulin; P Mercier
Journal:  Acta Diabetol Lat       Date:  1985 Oct-Dec

7.  Beta-cell function recovery is not the only factor responsible for remission in type I diabetics: evaluation of C-peptide secretion in diabetic children after first metabolic recompensation and at partial remission phase.

Authors:  E Schober; G Schernthaner; H Frisch; M Fink
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.